Skip to main content

RINVOQ (Abbvie Pty Ltd)

Product name
Date registered
Evaluation commenced
Decision date
Approval time
188 (255 working days)
Active ingredients
upadacitinib hemihydrate
Registration type

Non-radiographic Axial Spondyloarthritis

RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated Creactive protein (CRP) and/or magnetic resonance imaging (MRI) change, who have responded inadequately to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).

Help us improve the Therapeutic Goods Administration site